
Bavarian Nordic (CSE:BAVA) announced a DKK 810 million gain from a priority review voucher sale, to be booked in Q3 2025, which will elevate its full-year 2025 EBITDA margin guidance to 40-42% from the previous 26-30% (before special items). This comes as the biotech firm reported robust first-half revenue growth of 33% to nearly DKK 3 billion and an improved H1 EBITDA margin of 32%, while reaffirming its 2025 revenue outlook.
Bavarian Nordic has announced a significant, non-recurring gain of DKK 810 million from the sale of a priority review voucher, which will be recognized in the third quarter of 2025. This one-time event has prompted the company to raise its full-year 2025 EBITDA margin guidance to 40-42%. It is critical to note that the underlying operational guidance for EBITDA margin before special items remains unchanged at 26-30%, providing a clearer picture of sustainable profitability. The announcement is supported by robust fundamental performance, evidenced by a 33% year-over-year increase in first-half revenue to nearly DKK 3 billion. Furthermore, the company demonstrated substantial improvement in operational efficiency, with its first-half EBITDA margin before special items expanding to 32% from 20% in the prior-year period. The company's confidence is further underscored by the reaffirmation of its 2025 revenue guidance of DKK 6-6.60 billion.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment